China | Imports and Exports | World | Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products | Value (US$) and Value Growth, YoY (%) | 2012 - 2023
The value of exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from China totalled $ 797 million in 2023. Sales of commodity group 3002 from China decreased by 60% in value terms compared to 2022. exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" decreased by $ 1.22 billion (cumulative exports of commodity group 3002 from China amounted $2.02 billion in 2022)
Exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" amounted to 0.023% of total exports from China (cumulative merchandise exports from China totalled $ 3.37 trillion in 2023). The share of commodity group 3002 in total exports from China decreased by 0.032 p.p. compared to 2022 (it was 0.056% in 2022 and cumulative exports from China were equal to $ 3.59 trillion).
Exports of commodity group 3002 amounted to 7.07% of total sales of group "" from China in 2023 (the value of exports of commodity group from China amounted to $11.2 billion in 2023). The share of exports of commodity group 3002 in sales of commodity group from China lowered by 7.37 p.p. compared to 2022 (it was 14.4% in 2022, and exports of commodity group from China were $14 billion).
Where does China export Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc?
Top export destinations of "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from China in 2023:
- USA with a share of 19.7% (157 million US$)
- Brazil with a share of 12.9% (103 million US$)
- Italy with a share of 9.36% (74 million US$)
- Turkey with a share of 4.33% (34 million US$)
- Hong Kong with a share of 4.28% (34 million US$)
- Morocco with a share of 3.49% (27 million US$)
- Russia with a share of 3.48% (27 million US$)
- Thailand with a share of 2.89% (23 million US$)
- Netherlands with a share of 2.73% (21 million US$)
- Switzerland with a share of 2.56% (20 million US$)
Exports structure of 3002 - Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc - from China in 2023 represented by the following main commodity groups:
- 1.53% (12.2 million US$): 300290 - Human blood; animal blood prepared for therapeutic/prophylactic/diagnostic uses; toxins, cultures of micro-organisms (excl. yeasts) & sim. products
The value of imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" to China totalled $ 16.8 billion in 2023. Sales of commodity group 3002 to China went up by 11.2% compared to 2022: imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" went up by $ 1.7 billion (the value of imports of commodity group 3002 to China was equal to $15.1 billion in 2022)
Imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" accounted for 0.659% of total import flow to China (in 2023, total imports to China amounted to $ 2.55 trillion). The share of commodity group 3002 in total imports to China increased by 0.101 p.p. compared to 2022 (it was 0.558% in 2022 and cumulative imports to China were equal to $ 2.71 trillion).
Imports of commodity group 3002 reached 39% of total imports of group "" to China in 2023 (imports of commodity group to China totalled $43 billion in 2023). The share of purchases of commodity group 3002 in total imports of commodity group to China increased by 1.15 p.p. compared to 2022 (it was 38% in 2022, and imports of commodity group to China accounted for $39 billion).
Where does China import Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc from?
Top trading partners (import of "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc") of China in 2023:
- Ireland with a share of 39% (6.68 billion US$)
- USA with a share of 17.9% (3.03 billion US$)
- Switzerland with a share of 12.7% (2.15 billion US$)
- Germany with a share of 10.6% (1.8 billion US$)
- France with a share of 5.61% (947 million US$)
- Belgium with a share of 4.16% (702 million US$)
- Italy with a share of 1.73% (293 million US$)
- Spain with a share of 1.36% (230 million US$)
- Austria with a share of 1.22% (207 million US$)
- Japan - 153 million US$
Imports structure of 3002 - Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc - to China in 2023 represented by the following main commodity groups:
- 0.004% (813 thousand US$): 300290 - Human blood; animal blood prepared for therapeutic/prophylactic/diagnostic uses; toxins, cultures of micro-organisms (excl. yeasts) & sim. products
